These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 36177804)

  • 1. A case of de novo psoriasis secondary to atezolizumab in a patient with hepatocellular carcinoma.
    Lim JH; Lo Y
    Kaohsiung J Med Sci; 2022 Nov; 38(11):1135-1136. PubMed ID: 36177804
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
    Tsilimigras DI; Moris D
    J BUON; 2021; 26(2):637. PubMed ID: 34077021
    [No Abstract]   [Full Text] [Related]  

  • 4. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy.
    Ji F; Nguyen MH
    Lancet Oncol; 2022 Aug; 23(8):962-963. PubMed ID: 35798015
    [No Abstract]   [Full Text] [Related]  

  • 6. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage à trois" !
    Campion B; Larrey E; Wagner M; Rudler M; Thabut D; Allaire M
    Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101785. PubMed ID: 34384926
    [No Abstract]   [Full Text] [Related]  

  • 7. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal myositis and myasthenia induced by atezolizumab for the treatment of hepatocellular carcinoma.
    Dumortier J; Simon M; Bouhour F
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101854. PubMed ID: 34936927
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study-Should we extend the boundaries?
    Gulati P; Taneja S; Duseja A; Singh V
    Hepatology; 2022 Oct; 76(4):E80-E81. PubMed ID: 35503726
    [No Abstract]   [Full Text] [Related]  

  • 11. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
    Minot-This MS; Edeline J
    Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
    [No Abstract]   [Full Text] [Related]  

  • 12. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary Evaluation of Atezolizumab Plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation.
    Yang Z; Sun J; Zhuang L; Mou H; Zheng S
    Liver Transpl; 2022 May; 28(5):895-896. PubMed ID: 35090081
    [No Abstract]   [Full Text] [Related]  

  • 14. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
    N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
    Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phototoxic drug reaction with the novel agent rovalpituzumab tesirine.
    Hou JL; Bridges AG
    Int J Dermatol; 2018 Mar; 57(3):e17-e19. PubMed ID: 29319846
    [No Abstract]   [Full Text] [Related]  

  • 17. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?
    Rammohan A; Reddy MS; Farouk M; Vargese J; Rela M
    Hepatology; 2018 Mar; 67(3):1166-1168. PubMed ID: 29023959
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature.
    Singh B; Kaur P; Maroules M
    J Investig Med High Impact Case Rep; 2021; 9():2324709621992207. PubMed ID: 33787380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies.
    Liu X; Lu Y; Qin S
    Future Oncol; 2021 Jun; 17(17):2243-2256. PubMed ID: 33663220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.